NCT07650240: Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
- State
- Under way
- Phase
- Phase 2
- People
- 202 planned
- Started
- 4 Aug 2026
- Primary completion
- 30 Dec 2030
- Arms
- Arm A1 (177Lu-PSMA-617, iADT), Arm B1 (177Lu-PSMA-617, iADT, iAA, P)
- Results
- None posted
- 16 Jun 2026: Trial registered
- 4 Aug 2026: Trial started